1. Crea, F, Libby, P. Acute coronary syndromes: the way forward from mechanisms to precision treatment. Circulation 2017; 136: 1155–1166.
Google Scholar | Crossref | Medline2. Sibbing, D, Angiolillo, DJ, Huber, K. Antithrombotic therapy for acute coronary syndrome: past, present and future. Thromb Haemost 2017; 117: 1240–1248.
Google Scholar | Crossref | Medline3. Thomas, MR, Storey, RF. Effect of P2Y12 inhibitors on inflammation and immunity. Thromb Haemost 2015; 114: 490–497.
Google Scholar | Crossref | Medline4. Korniluk, A, Koper-Lenkiewicz, OM, Kamińska, J, Kemona, H, Dymicka-Piekarska, V. Mean Platelet Volume (MPV): new perspectives for an old marker in the course and prognosis of inflammatory conditions. Mediat Inflamm 2019; 2019: 1–14.
Google Scholar | Crossref5. Budzianowski, J, Pieszko, K, Burchardt, P, Rzeźniczak, J, Hiczkiewicz, J. The role of hematological indices in patients with acute coronary syndrome. Dis Markers 2017; 2017: 3041565.
Google Scholar | Crossref | Medline6. Małyszczak, A, Łukawska, A, Dylag, I, Lis, W, Mysiak, A, Kuliczkowski, W. Blood platelet count at hospital admission impacts long-term mortality in patients with acute coronary syndrome. Cardiol 2020; 145: 148–154.
Google Scholar | Crossref | Medline7. Budzianowski, J, Pieszko, K, Burchardt, P, Rzeźniczak, J, Hiczkiewicz, J. The role of hematological indices in patients with acute coronary syndrome. Dis Markers 2017; 2017: 3041565.
Google Scholar | Crossref | Medline8. Eisen, A, Bental, T, Assali, A, Kornowski, R, Lev, EI. Mean platelet volume as a predictor for long-term outcome after percutaneous coronary intervention. J Thromb Thrombolysis 2013; 36: 469–474.
Google Scholar | Crossref | Medline | ISI9. Choi, S-W, Choi, D-H, Kim, H-W, Ku, Y-H, Ha, S-I, Park, G. Clinical outcome prediction from mean platelet volume in patients undergoing percutaneous coronary intervention in Korean cohort: implications of more simple and useful test than platelet function testing. Platelets 2014; 25: 322–327.
Google Scholar | Crossref | Medline | ISI10. Niu, X, Yang, C, Zhang, Y, Zhang, H, Yao, Y. Mean platelet volume on admission improves risk prediction in patients with acute coronary syndromes. Angiology 2015; 66: 456–463.
Google Scholar | SAGE Journals | ISI11. Ulucan, Ş, Keser, A, Kaya, Z, et al. Association between PDW and long term major adverse cardiac events in patients with acute coronary syndrome. Heart Lung Circ 2016; 25: 29–34.
Google Scholar | Crossref | Medline12. Timóteo, AT, Papoila, AL, Lousinha, A, et al. Predictive impact on mediumterm mortality of hematological parameters in Acute Coronary Syndromes: added value on top of GRACE risk score. Eur Heart J: Acute Cardiovascular Care 2015; 4: 172–179.
Google Scholar | SAGE Journals | ISI13. Wasilewski, J, Desperak, P, Hawranek, M, et al. Prognostic implications of mean platelet volume on short- and long-term outcomes among patients with non-ST-segment elevation myocardial infarction treated with percutaneous coronary intervention: A single-center large observational study. Platelets 2016; 27: 452–458.
Google Scholar | Crossref | Medline14. Bolat, I, Akgul, O, Cakmak, HA, et al. The prognostic value of admission mean platelet volume to platelet count ratio in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Kardiol Pol 2016; 74: 346–355.
Google Scholar | Crossref | Medline | ISI15. Giustino, G, Kirtane, AJ, Généreux, P, et al. Relation between platelet count and platelet reactivity to thrombotic and bleeding risk: from the assessment of dual antiplatelet therapy with drug-eluting stents study. Am J Cardiol 2016; 117: 1703–1713.
Google Scholar | Crossref | Medline16. Ly, HQ, Kirtane, AJ, Murphy, SA, et al. Association of platelet counts on presentation and clinical outcomes in ST-elevation myocardial infarction (from the TIMI Trials). Am J Cardiol 2006; 98: 1–5.
Google Scholar | Crossref | Medline | ISI17. Nikolsky, E, Grines, CL, Cox, DA, et al. Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC Trial). Am J Cardiol 2007; 99: 1055–1061.
Google Scholar | Crossref | Medline | ISI18. Song, PS, Ahn, KT, Jeong, JO, et al. Association of baseline platelet count with all-cause mortality after acute myocardial infarction. Eur Heart J. Acute Cardiovasc Care 2020; Online ahead of print: 2048872620925257.
Google Scholar19. Oikonomou, EK, Repanas, TI, Papanastasiou, C, et al. The effect of in-hospital acquired thrombocytopenia on the outcome of patients with acute coronary syndromes: a systematic review and meta-analysis. Thromb Res 2016; 147: 64–71.
Google Scholar | Crossref | Medline20. Boulmpou, A, Kartas, A, Farmakis, I, et al. Motivational interviewing to support LDL-C therapeutic goals and lipid-lowering therapy compliance in patients with acute coronary syndromes (IDEAL-LDL) study: rationale and design. Hellenic J Cardiol 2019; 60: 249–253.
Google Scholar | Crossref | Medline21. Farmakis, I, Zafeiropoulos, S, Kartas, A, et al. Treatment practices and lipid profile of patients with acute coronary syndrome: results from a tertiary care hospital. Acta Cardiol 2020; 75: 527–534.
Google Scholar | Crossref | Medline22. Lancé, MD . Mean platelet volume needs standardisation. Thromb Haemostasis 2015; 113: 908.
Google Scholar | Crossref | Medline23. Thygesen, K, Alpert, JS, Jaffe, AS, et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol 2018; 72: 2231–2264.
Google Scholar | Crossref | Medline24. Hicks, KA, Tcheng, JE, Bozkurt, B, et al. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association Task Force on clinical data standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). Circulation 20142015; 132: 302–361.
Google Scholar | Medline25. Gibson, CM, Mega, JL, Burton, P, et al. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J 2011; 161: 815–821.
Google Scholar | Medline | ISI26. Turner, SJ, Ketch, TR, Gandhi, SK, Sane, DC. Routine hematologic clinical tests as prognostic markers in patients with acute coronary syndromes. Am Heart J 2008; 155: 806–816.
Google Scholar | Crossref | Medline | ISI27. Turakhia, MP, Murphy, SA, Pinto, TL, et al. Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Am J Cardiol 2004; 94: 1406–1410.
Google Scholar | Crossref | Medline | ISI28. Von Hundelshausen, P, Weber, C. Platelets as immune cells: Bridging inflammation and cardiovascular disease. Circ Res 2007; 100: 27–40.
Google Scholar | Crossref | Medline | ISI29. Gasparyan, AY, Ayvazyan, L, Mukanova, U, Yessirkepov, M, Kitas, GD. The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases. Ann Lab Med 2019; 39: 345–357.
Google Scholar | Crossref | Medline30. Lee, S, Hizoh, I, Kovacs, A, et al. Predictors of high on-clopidogrel platelet reactivity in patients with acute coronary syndrome. Platelets 2016; 27: 159–167.
Google Scholar | Crossref | Medline31. Ray, KK, Cannon, CP. Pathological changes in acute coronary syndromes: the role of statin therapy in the modulation of inflammation, endothelial function and coagulation. J Thromb Thrombolysis 2004; 18: 89–101.
Google Scholar | Crossref | Medline32. EPILOG Investigators . Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689–1696.
Google Scholar | Crossref | Medline | ISI33. Vonderheide, RH, Thadhani, R, Kuter, DJ. Association of thrombocytopenia with the use of intra-aortic balloon pumps. Am J Med 1998; 105: 27–32.
Google Scholar | Crossref | Medline | ISI34. De Luca, G, Santagostino, M, Secco, GG, et al. Mean platelet volume and the extent of coronary artery disease: results from a large prospective study. Atherosclerosis 2009; 206: 292–297.
Google Scholar | Crossref | Medline | ISI35. Taskesen, T, Sekhon, H, Wroblewski, I, et al. Usefulness of mean platelet volume to predict significant coronary artery disease in patients with non-ST-elevation acute coronary syndromes. Am J Cardiol 2017; 119: 192–196.
Google Scholar | Crossref | Medline36. Beyan, C, Kaptan, K, Ifran, A. Platelet count, mean platelet volume, platelet distribution width, and plateletcrit do not correlate with optical platelet aggegation responses in healthy volunteers. J Thromb Thrombolysis 2006; 22: 161–164.
Google Scholar | Crossref | Medline | ISI37. Li, S, Liu, H, Liu, J. Predictive performance of adding platelet reactivity on top of CRUSADE score for 1-year bleeding risk in patients with acute coronary syndrome. J Thromb Thrombolysis 2016; 42: 360–368.
Google Scholar | Crossref | Medline38. Ismail, N, Jordan, KP, Kadam, UT, Edwards, JJ, Kinnaird, T, Mamas, MA. Bleeding after hospital discharge following acute coronary syndrome: incidence, types, timing, and predictors. J Am Heart Ass 2019; 8: e013679.
Google Scholar | Medline39. Altman, DG, Royston, P. The cost of dichotomising continuous variables. BMJ (Clinical Research Ed.) 2006; 332: 1080.
Google Scholar | Crossref | Medline